Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?
Whether or not olanzapine causes bone marrow toxicity is still a matter of debate. In spite of pre-marketing and post-marketing clinical trials, and although there have been no cases in animals of olanzapine-induced neutropenia or agranulocytosis, the risk of bone marrow toxicity cannot be excluded. The present paper addresses the following questions: what is the potential background of drug-induced agranulocytosis? Are there any case reports supporting the view that olanzapine has relevant bone marrow toxicity? What strategies might be helpful in identifying the pathological mechanisms underlying this side effect?
Dettling
M
M
Department of Psychiatry, Freie Universität Berlin, Germany.
Cascorbi
I
I
Hellweg
R
R
Deicke
U
U
Weise
L
L
Müller-Oerlinghausen
B
B
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000235:genetics; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006680:HLA Antigens / Q000145:classification / Q000235:genetics*; D006239:Haplotypes; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives*
D014150:Antipsychotic Agents; D006680:HLA Antigens; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine